BAL Fluid Biomarkers in Sarcoma

University Health Network, Toronto

Status and phase: Not yet enrolling; Phase 2

Conditions: Bronchoalveolar Lavage Fluid; Soft Tissue Sarcoma (STS); Bronchoalveolar Lavage (BAL)

Treatments: Procedure: Bronchoscopy & Metastasectomy

Study type: Interventional

Funder types: Other

Identifiers

NCT06815666

24-5871

Details and patient eligibility

About

This is a single-centre, Phase II, prospective study designed to assess BALF and TA-derived biomarkers in relation to metastatic burden in STS patients. BALF and TA samples will be collected during routine bronchoscopy performed as part of standard care at Toronto General Hospital (TGH). Additionally, tissue samples of lung metastases and adjacent normal lung will be collected and used to correlate the identified biomarkers.

Enrollment: 70 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age ≥ 18 years
2. Ability to understand and willingness to sign a written informed consent document
3. Diagnosed with soft tissue sarcoma
4. Undergoing resection of lung lesion as part of standard care

Exclusion criteria

1. History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for ≥ 2 years

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

70 participants in 1 patient group

Routine Bronchoscopy & SOC Metastasectomy

Experimental group

Description:

BALF and TA will be collected during routine bronchoscopy, and resected lung metastases and adjacent normal tissue will be collected during standard of care metastasectomy

Treatment:

Procedure: Bronchoscopy & Metastasectomy